Table 3. Long-term visual acuity according to clinical and evolutive characteristics (univariate analysis).
| Characteristics | All patients | Patients with VA | WHO | WHO | WHO | p | OR* | [95% CI] |
|---|---|---|---|---|---|---|---|---|
| n = 180 (%)a | n = 132 (%)a | 0, 1 and 2 | 3, 4 and 5 | md | ||||
| n = 97 (%)b | n = 35 (%)b | n = 48 (%)c | ||||||
| Sex | ||||||||
| - male | 84 (46.6%) | 62 (46.9%) | 48 (76.2%) | 15 (23.8%) | 21 (25%) | 0.57 | 0.8 | 0.3–17 |
| - female | 96 (53.4%) | 70 (53.1%) | 49 (71%) | 20 (29%) | 27 (28.1%) | |||
| - sex ratio (M/F) | 0.87 | 0.88 | 0.98 | 0.75 | 0.85 | |||
| Age (years) | 0.001 | 4.6** | 1.9–10.9 | |||||
| - < 1 | 45 (25%) | 31 (23.5%) | 15 (48.3%) | 16 (51.7%) | 14 (31.1%) | |||
| -5 | 102 (56.7%) | 76 (57.6%) | 62 (81.6%) | 14 (18.4%) | 26 (25.5%) | |||
| - ≥ 5 | 33 (18.3%) | 25 (18.9%) | 20 (80%) | 5 (20%) | 8 (24.2%) | |||
| - Median (IQR) | 2.4 (1–4.2) | |||||||
| Year of diagnosis | ||||||||
| - 1990–2000 | 99 (55%) | 70 (53.1%) | 49 (68.9%) | 22 (31.1%) | 28 (28.3%) | 0.17 | 0.6 | 0.2–1.2 |
| - ≥ 2000 | 81 (45%) | 62 (46.9%) | 48 (78.6%) | 13 (21.4%) | 20 (24.7%) | |||
| NF1 | 0.1 | 0.4 | 0.2–12 | |||||
| - yes | 60 (33.3%) | 46 (34.8%) | 38 (81.7%) | 8 (18.3%) | 14 (23.3%) | |||
| - no | 120 (66.7%) | 86 (65.2%) | 59 (68.6%) | 27 (31.4%) | 34 (28.3%) | |||
| Diencephalic syndrome | ||||||||
| - yes | 32 (17.8%) | 23 (17.4%) | 14 (60.9%) | 9 (39.1%) | 9 (28.1%) | 0.13 | 2.0 | 0.8–5.2 |
| - no | 148 (82.2%) | 109 (82.6%) | 83 (76.1%) | 26 (23.9%) | 39 (26.3%) | |||
| Intracranial hypertension | ||||||||
| - yes | 48 (26.7%) | 31 (23.5%) | 23 (74.2%) | 8 (25.8%) | 17 (35.4%) | 0.92 | 0.9 | 0.3–2.4 |
| - no | 132 (73.3%) | 101 (76.5%) | 74 (73.2%) | 27 (26.8%) | 31 (23.5%) | |||
| Length of follow-up (years) | ||||||||
| - < 5 | 12 (6.7%) | 2 (1.5%) | 2 (100%) | 0 (0%) | 10 (83.3%) | 0.17 | 1.0 | 0.9–12 |
| - ≥ 5 et < 10 | 33 (18.3%) | 20 (15.1%) | 18 (90%) | 2 (10%) | 13 (39.4%) | |||
| - ≥ 10 et < 15 | 88 (48.9%) | 70 (53%) | 48 (68.5%) | 22 (31.5%) | 18 (20.4%) | |||
| - ≥ 15 | 47 (26.1%) | 40 (30.4%) | 29 (72.5%) | 11 (27.5%) | 7 (14.9%) | |||
| Evolution | ||||||||
| - living | 123 (68%) | 118 (89%) | 91 (77.1%) | 27 (22.9%) | 5 (4%) | |||
| - deceased | 36 (20%) | 14 (11%) | 6 (42.9%) | 8 (57.1%) | 22 (61%) | 0.01 | 4.5 | 1.4–14.1 |
| - lost to follow-up or refusals | 21 (12%) | - | - | 21 (100%) | ||||
| Subsequent chemotherapy | ||||||||
| 0 | 83 (46.1%) | 60 (45.5%) | 50 (83.4%) | 10 (16.6%) | 23 (27.7%) | 0.02 | 2.5 | 1.1–5.8 |
| - 1 to 3 | 81 (45%) | 59 (44.7%) | 41 (69.5%) | 18 (30.5%) | 22 (27.2%) | |||
| - 4 to 5 | 12 (6.7%) | 10 (7.6%) | 4 (40%) | 6 (60%) | 2 (16.7%) | |||
| - ≥ 6 | 4 (2.2%) | 3 (2.2%) | 2 (66.7%) | 1 (33.3%) | 1 (25%) | |||
| Specific treatment other than chemotherapy | ||||||||
| - Surgery (partial resection) | 30 (16.7%) | 22 (16.7%) | 13 (59.1%) | 9 (40.9%) | 8 (26.7%) | 0.002 | 1.5 | 1.6–8.1 |
| - Radiotherapy | 28 (15.6%) | 20 (15.1%) | 15 (75%) | 5 (25%) | 8 (28.6%) | 0.07 | 2.1 | 0.09–4.6 |
| - Surgery + Radiotherapy | 27 (15%) | 24 (18.2%) | 13 (54.2%) | 11 (45.8%) | 3 (6.2%) | 0.02 | 2.9 | 1.2–7.4 |
| - No specific treatment other than chemotherapy | 95 (52.7%) | 66 (50%) | 56 (84.8%) | 10 (15.2%) | 29 (30.5%) | 0.004 | 3.4 | 1.5–7.8 |
| Surgical procedures for intracranial hypertension | ||||||||
| - 0 surgical procedure | 111 (61.7%) | 85 (64.4%) | 73 (85.8%) | 12 (14.2%) | 26 (23.4%) | <10−3 | 5.8 | 2.5–13.4 |
| - 1 surgical procedure | 20 (11.1%) | 11 (8.3%) | 5 (45.5%) | 6 (54.5%) | 9 (45%) | |||
| - 2 to 4 surgical procedures | 38 (21.1%) | 29 (21.9%) | 17 (58.6%) | 12 (41.4%) | 9 (23.7%) | |||
| - ≥ 5 surgical procedures | 11 (6.1%) | 7 (5.4%) | 2 (28.6%) | 5 (71.4%) | 4 (36.4%) | |||
| Treatment after BB-SFOP chemotherapy (second-line chemotherapy and/or surgery and/or radiotherapy) | ||||||||
| - No treatment | 55 (30.5%) | 40 (30.3%) | 37 (92.5%) | 3 (7.5%) | 15 (27.3%) | 0.008 | 4.5 | 1.5–14 |
| - Treatment | 125 (69.5%) | 92 (69.7%) | 60 (65.2%) | 32 (34.8%) | 33 (26.4%) | |||
a: column percentages;
b: row percentages (n = patients with VA);
c: row percentages (n = all patients)
*WHO 0, 1 and 2 vs WHO 3, 4 and 5;
**< 1 vs ≥ 1